Product Code: RP-ID-10151834 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151834
Market Overview:
Global Perennial Allergic Rhinitis Industry Market Research 2022-2030
"Allergic rhinitis, usually identified as hay fever, is an allergic reaction to specific allergens present in the patient's surrounding environment. A common cause of allergic reactions is an increase in the amount of pollen in the air. In the case of seasonal allergic rhinitis, pollen is the most popular allergen. Mold, animal dander and dust are other substances that can cause allergic rhinitis. Allergic rhinitis causes the patient's eyes to shed tears, runny nose, constant sneezing, swelling and redness near the eyes. Allergic rhinitis occurs in seasonal, perennial or occupational rhinitis. The symptoms of seasonal allergic rhinitis manifest in spring, summer and early fall.
They are usually caused by an allergy to airborne mold pollen from trees, lawns and weeds. People with perennial allergic rhinitis will have symptoms all year round. It is usually caused by pet hair or dander, dust mites, cockroaches or mold. Potential food allergies rarely cause perennial nasal symptoms.
Overview of the global allergic rhinitis market :
Raising awareness of allergic reactions in people around the world is the main factor that is expected to drive the growth of the global allergic rhinitis market. In addition, the availability of various modes of administration provided by drug manufacturers is contributing to growth.
In addition, the market is expected to grow due to the quality of drugs and nasal sprays produced by manufacturers for effective treatment of allergic rhinitis. This is expected to stimulate the market during the forecast period. In addition, heavy use of tobacco is another factor that increases the prevalence of allergic rhinitis. With the increase in tobacco use, the global market for allergic rhinitis is also increasing.
People actively expect these factors to promote the growth of the global allergic rhinitis market. You will face certain restrictions and obstacles that will limit the growth of the market. Factors such as patent expiration, competition from generic drugs, and growing preference for complementary and alternative therapies are potential limiting factors hindering the overall growth of the global allergic rhinitis market. However, technological progress and untapped potential in emerging markets provide promising growth opportunities.
Allergic rhinitis market, according to treatment:
• Immunotherapy
• Antihistamines
• Decongestants
• Corticosteroids
• Others
According to treatment, the market is divided into immunotherapy, antihistamines, decongestants, corticosteroids, etc. During the forecast period, the market share of antihistamines is the largest. Antihistamines help treat allergic rhinitis and other allergies.
People view antihistamines as a cheap over-the-counter medicine that can relieve nasal congestion and sneezing. The market is divided into skin test, radioactive allergen IgE test (RAST), and complete blood count. The IgE radioactive adsorbent (RAST) test segment has the largest market share during the forecast period. This test checks your blood for specific IgE antibodies to determine which substances you may be allergic to.
Key players :
Allergic Rhinitis Market" research report will provide valuable insights from major players, focusing on global markets, including Merck, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, ALK-Abell, Meda Pharmaceuticals, etc. Some of the major players are AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industry Co., Ltd. and Alcon (Novartis AG).
Major developments:
partnerships, cooperation and agreements • In February 2020, Hikma Pharmaceuticals PLC (Hikma, Group), a generic multinational pharmaceutical company, and Glenmark Specialty SA, the Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company, announced an exclusive license agreement with the United States , Used to sell Ryaltris™ (Momethasone furoate olopatadine hydrochloride nasal spray), which is an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR).
2. Acquisitions and mergers • In November 2020, Dr. Reddys Laboratories announced that it has reached a definitive agreement with Glenmark Pharmaceuticals to acquire the Momat Rino brand (applicable to Russia, Kazakhstan and Uzbekistan) upon completion of certain previous actions and closure activities. Momat. Rino Advance (Russia), Momat A (Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (Ukraine) 3. Product launch and expansion • In May 2021, Glenmark Pharma launched Ryaltris nasal spray for the treatment of moderate to severe Allergic rhinitis in India. • In June 2018, Innovus Pharmaceuticals, Inc announced the launch of its AllerVarx™ product, which is a natural health product that has been clinically tested and approved by Health Canada to help reduce the symptoms of allergic rhinitis, such as runny nose, Sneezing, stuffy nose and itching."
Related Reports
Proof of Quality & Reliability
